| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Panic Disorder | 125 | 2016 | 133 | 12.540 |
Why?
|
| Anxiety Disorders | 104 | 2023 | 163 | 11.980 |
Why?
|
| Stress Disorders, Post-Traumatic | 52 | 2022 | 219 | 6.370 |
Why?
|
| Phobic Disorders | 55 | 2014 | 64 | 5.880 |
Why?
|
| Cycloserine | 20 | 2023 | 26 | 3.840 |
Why?
|
| Anti-Anxiety Agents | 31 | 2014 | 38 | 3.690 |
Why?
|
| Adult | 237 | 2021 | 6896 | 3.440 |
Why?
|
| Refugees | 21 | 2011 | 25 | 3.420 |
Why?
|
| Humans | 352 | 2023 | 22823 | 2.880 |
Why?
|
| Male | 248 | 2020 | 12400 | 2.850 |
Why?
|
| Female | 259 | 2020 | 12904 | 2.820 |
Why?
|
| Veterans | 13 | 2022 | 87 | 2.640 |
Why?
|
| Clonazepam | 22 | 2014 | 26 | 2.450 |
Why?
|
| Depressive Disorder | 40 | 2019 | 163 | 2.340 |
Why?
|
| Middle Aged | 171 | 2019 | 7873 | 2.330 |
Why?
|
| Treatment Outcome | 89 | 2023 | 2934 | 2.320 |
Why?
|
| Double-Blind Method | 53 | 2020 | 373 | 2.200 |
Why?
|
| Antidepressive Agents | 30 | 2017 | 88 | 2.170 |
Why?
|
| Psychiatric Status Rating Scales | 72 | 2017 | 267 | 2.160 |
Why?
|
| Anxiety | 29 | 2023 | 143 | 2.120 |
Why?
|
| Bipolar Disorder | 21 | 2009 | 99 | 2.070 |
Why?
|
| Implosive Therapy | 11 | 2023 | 19 | 2.040 |
Why?
|
| Benzodiazepines | 26 | 2010 | 45 | 1.970 |
Why?
|
| Fear | 23 | 2023 | 45 | 1.970 |
Why?
|
| Sertraline | 14 | 2014 | 24 | 1.950 |
Why?
|
| Paroxetine | 9 | 2008 | 14 | 1.910 |
Why?
|
| Cyclohexanols | 8 | 2014 | 18 | 1.790 |
Why?
|
| Antipsychotic Agents | 12 | 2012 | 50 | 1.750 |
Why?
|
| Severity of Illness Index | 55 | 2020 | 795 | 1.620 |
Why?
|
| Combined Modality Therapy | 36 | 2023 | 294 | 1.580 |
Why?
|
| Comorbidity | 54 | 2013 | 426 | 1.460 |
Why?
|
| Agoraphobia | 28 | 2009 | 28 | 1.420 |
Why?
|
| Piperazines | 10 | 2012 | 82 | 1.350 |
Why?
|
| Fluoxetine | 14 | 2008 | 34 | 1.340 |
Why?
|
| gamma-Aminobutyric Acid | 8 | 2009 | 25 | 1.320 |
Why?
|
| Antidepressive Agents, Second-Generation | 11 | 2008 | 28 | 1.300 |
Why?
|
| Antimetabolites | 7 | 2019 | 12 | 1.290 |
Why?
|
| Anticonvulsants | 10 | 2009 | 51 | 1.270 |
Why?
|
| Somatoform Disorders | 10 | 2010 | 14 | 1.250 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 5 | 2020 | 103 | 1.190 |
Why?
|
| Opioid-Related Disorders | 9 | 2019 | 57 | 1.130 |
Why?
|
| Cross-Cultural Comparison | 7 | 2010 | 36 | 1.090 |
Why?
|
| Piracetam | 4 | 2009 | 7 | 1.080 |
Why?
|
| Phobia, Social | 7 | 2023 | 13 | 1.080 |
Why?
|
| Substance-Related Disorders | 13 | 2012 | 87 | 1.070 |
Why?
|
| Stress, Psychological | 12 | 2018 | 206 | 1.040 |
Why?
|
| Thiophenes | 5 | 2010 | 11 | 1.010 |
Why?
|
| Adolescent | 62 | 2019 | 1874 | 1.000 |
Why?
|
| Drug Therapy, Combination | 24 | 2014 | 162 | 0.980 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 20 | 2021 | 38 | 0.970 |
Why?
|
| Quality of Life | 15 | 2012 | 559 | 0.950 |
Why?
|
| Alprazolam | 19 | 2010 | 19 | 0.880 |
Why?
|
| Nipecotic Acids | 4 | 2008 | 4 | 0.860 |
Why?
|
| Emotions | 9 | 2014 | 69 | 0.850 |
Why?
|
| Extinction, Psychological | 7 | 2023 | 12 | 0.840 |
Why?
|
| Arousal | 8 | 2017 | 48 | 0.840 |
Why?
|
| Personality Inventory | 25 | 2008 | 68 | 0.820 |
Why?
|
| Drug Administration Schedule | 22 | 2020 | 151 | 0.810 |
Why?
|
| Psychotherapy, Group | 9 | 2019 | 37 | 0.800 |
Why?
|
| Citalopram | 6 | 2013 | 8 | 0.790 |
Why?
|
| Adaptation, Psychological | 10 | 2018 | 165 | 0.780 |
Why?
|
| Depressive Disorder, Major | 11 | 2012 | 88 | 0.770 |
Why?
|
| Behavior Therapy | 7 | 2013 | 85 | 0.760 |
Why?
|
| Ambulatory Care | 16 | 2011 | 66 | 0.750 |
Why?
|
| Prevalence | 21 | 2009 | 375 | 0.740 |
Why?
|
| Antidepressive Agents, Tricyclic | 8 | 2009 | 15 | 0.740 |
Why?
|
| Placebos | 22 | 2020 | 63 | 0.730 |
Why?
|
| Monoamine Oxidase Inhibitors | 11 | 2005 | 16 | 0.730 |
Why?
|
| Psychotherapy | 7 | 2013 | 38 | 0.730 |
Why?
|
| Outpatients | 5 | 2014 | 56 | 0.710 |
Why?
|
| Azabicyclo Compounds | 3 | 2011 | 3 | 0.710 |
Why?
|
| Morals | 2 | 2018 | 13 | 0.700 |
Why?
|
| Substance Withdrawal Syndrome | 7 | 2010 | 34 | 0.690 |
Why?
|
| Hypnotics and Sedatives | 3 | 2011 | 20 | 0.680 |
Why?
|
| Cambodia | 18 | 2011 | 19 | 0.680 |
Why?
|
| Aged | 53 | 2019 | 7412 | 0.680 |
Why?
|
| Dose-Response Relationship, Drug | 22 | 2011 | 312 | 0.670 |
Why?
|
| Quinolones | 5 | 2012 | 11 | 0.670 |
Why?
|
| Drug Resistance | 6 | 2011 | 45 | 0.620 |
Why?
|
| Military Personnel | 5 | 2020 | 37 | 0.610 |
Why?
|
| Young Adult | 25 | 2019 | 1647 | 0.610 |
Why?
|
| Surveys and Questionnaires | 24 | 2017 | 1019 | 0.600 |
Why?
|
| Bupropion | 5 | 2005 | 6 | 0.600 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 3 | 2008 | 3 | 0.590 |
Why?
|
| United States | 21 | 2019 | 1762 | 0.580 |
Why?
|
| Brain | 16 | 2015 | 1202 | 0.570 |
Why?
|
| September 11 Terrorist Attacks | 3 | 2007 | 7 | 0.570 |
Why?
|
| War Exposure | 1 | 2018 | 4 | 0.570 |
Why?
|
| Duloxetine Hydrochloride | 5 | 2010 | 9 | 0.560 |
Why?
|
| Sleep Wake Disorders | 5 | 2013 | 108 | 0.560 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 2 | 0.560 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 18 | 0.550 |
Why?
|
| Virtual Reality Exposure Therapy | 2 | 2014 | 7 | 0.550 |
Why?
|
| GABA Agonists | 2 | 2008 | 3 | 0.550 |
Why?
|
| Melanoma | 1 | 2018 | 48 | 0.530 |
Why?
|
| Models, Psychological | 8 | 2010 | 58 | 0.530 |
Why?
|
| Sleep Paralysis | 3 | 2005 | 4 | 0.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 240 | 0.490 |
Why?
|
| Iraq War, 2003-2011 | 2 | 2017 | 7 | 0.480 |
Why?
|
| Diagnosis, Differential | 16 | 2010 | 309 | 0.480 |
Why?
|
| Psychometrics | 12 | 2013 | 175 | 0.480 |
Why?
|
| Relaxation Therapy | 3 | 2011 | 4 | 0.460 |
Why?
|
| Follow-Up Studies | 23 | 2013 | 1412 | 0.460 |
Why?
|
| Delayed-Action Preparations | 9 | 2008 | 28 | 0.450 |
Why?
|
| Meditation | 4 | 2017 | 21 | 0.450 |
Why?
|
| Child | 27 | 2019 | 1153 | 0.450 |
Why?
|
| Hypotension, Orthostatic | 5 | 2009 | 10 | 0.440 |
Why?
|
| Life Change Events | 6 | 2011 | 33 | 0.440 |
Why?
|
| Pilot Projects | 15 | 2019 | 370 | 0.430 |
Why?
|
| Mindfulness | 4 | 2020 | 46 | 0.430 |
Why?
|
| Prospective Studies | 16 | 2011 | 1487 | 0.430 |
Why?
|
| Research Design | 1 | 2015 | 157 | 0.420 |
Why?
|
| Mood Disorders | 6 | 2014 | 23 | 0.420 |
Why?
|
| Dizziness | 6 | 2008 | 17 | 0.420 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2013 | 21 | 0.420 |
Why?
|
| Suicide, Attempted | 6 | 2006 | 14 | 0.420 |
Why?
|
| Panic | 11 | 1991 | 11 | 0.410 |
Why?
|
| Depression | 9 | 2019 | 368 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2008 | 243 | 0.400 |
Why?
|
| Endpoint Determination | 3 | 2008 | 22 | 0.400 |
Why?
|
| Child Abuse | 4 | 2015 | 28 | 0.400 |
Why?
|
| Methadone | 6 | 2012 | 6 | 0.400 |
Why?
|
| Longitudinal Studies | 20 | 2009 | 1047 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2015 | 858 | 0.400 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2012 | 9 | 0.400 |
Why?
|
| Remission Induction | 7 | 2013 | 89 | 0.390 |
Why?
|
| Models, Statistical | 3 | 2013 | 112 | 0.390 |
Why?
|
| Medication Adherence | 2 | 2012 | 49 | 0.380 |
Why?
|
| Case-Control Studies | 14 | 2020 | 481 | 0.380 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2009 | 6 | 0.370 |
Why?
|
| Cross-Sectional Studies | 18 | 2017 | 759 | 0.370 |
Why?
|
| Serotonin Uptake Inhibitors | 2 | 2002 | 2 | 0.360 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 6 | 2005 | 31 | 0.360 |
Why?
|
| Attention | 6 | 2017 | 101 | 0.360 |
Why?
|
| Long-Term Care | 5 | 2005 | 55 | 0.360 |
Why?
|
| Mental Health Services | 4 | 2009 | 35 | 0.360 |
Why?
|
| Glutamine | 2 | 2009 | 5 | 0.350 |
Why?
|
| Glutamic Acid | 2 | 2009 | 18 | 0.350 |
Why?
|
| Prognosis | 10 | 2015 | 714 | 0.350 |
Why?
|
| Psychotropic Drugs | 4 | 2008 | 25 | 0.350 |
Why?
|
| Venlafaxine Hydrochloride | 7 | 2014 | 17 | 0.340 |
Why?
|
| HIV Infections | 2 | 2012 | 430 | 0.340 |
Why?
|
| Massachusetts | 12 | 2014 | 16 | 0.340 |
Why?
|
| Affect | 4 | 2018 | 57 | 0.340 |
Why?
|
| Culture | 1 | 2011 | 23 | 0.340 |
Why?
|
| Sex Offenses | 3 | 2020 | 23 | 0.330 |
Why?
|
| Semantics | 1 | 2010 | 13 | 0.330 |
Why?
|
| Health Status | 6 | 2007 | 200 | 0.320 |
Why?
|
| Mental Disorders | 9 | 2004 | 134 | 0.320 |
Why?
|
| Cognition | 8 | 2018 | 947 | 0.320 |
Why?
|
| Risk Factors | 18 | 2013 | 1966 | 0.320 |
Why?
|
| Dreams | 1 | 2009 | 2 | 0.310 |
Why?
|
| Safety | 1 | 2009 | 34 | 0.310 |
Why?
|
| Interviews as Topic | 5 | 2018 | 109 | 0.300 |
Why?
|
| Personality Disorders | 9 | 2005 | 12 | 0.300 |
Why?
|
| Cues | 3 | 2013 | 37 | 0.300 |
Why?
|
| Neck | 2 | 2006 | 23 | 0.300 |
Why?
|
| GABA Modulators | 3 | 2004 | 4 | 0.300 |
Why?
|
| Lipopolysaccharides | 5 | 1997 | 82 | 0.300 |
Why?
|
| Phototherapy | 2 | 2019 | 27 | 0.300 |
Why?
|
| Chest Pain | 3 | 2006 | 20 | 0.300 |
Why?
|
| Dyspnea | 3 | 2006 | 35 | 0.290 |
Why?
|
| Analysis of Variance | 7 | 2012 | 228 | 0.290 |
Why?
|
| Interview, Psychological | 8 | 2013 | 39 | 0.290 |
Why?
|
| Tinnitus | 1 | 2008 | 7 | 0.280 |
Why?
|
| Sex Factors | 13 | 2009 | 384 | 0.280 |
Why?
|
| Dibenzothiazepines | 1 | 2008 | 2 | 0.280 |
Why?
|
| Patient Compliance | 6 | 2008 | 145 | 0.280 |
Why?
|
| Central Nervous System Diseases | 2 | 2008 | 13 | 0.280 |
Why?
|
| Neurosciences | 1 | 2008 | 9 | 0.280 |
Why?
|
| Facial Expression | 3 | 2013 | 8 | 0.270 |
Why?
|
| Central Nervous System | 2 | 2008 | 47 | 0.270 |
Why?
|
| Nootropic Agents | 1 | 2007 | 11 | 0.270 |
Why?
|
| Smell | 2 | 2004 | 12 | 0.270 |
Why?
|
| Vestibular Diseases | 2 | 2005 | 3 | 0.270 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2007 | 2 | 0.260 |
Why?
|
| Child Abuse, Sexual | 2 | 2009 | 9 | 0.260 |
Why?
|
| Time Factors | 11 | 2008 | 1258 | 0.260 |
Why?
|
| Reproducibility of Results | 9 | 2014 | 591 | 0.260 |
Why?
|
| Triazoles | 2 | 1998 | 28 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 5 | 1997 | 164 | 0.260 |
Why?
|
| Obsessive-Compulsive Disorder | 5 | 2017 | 15 | 0.260 |
Why?
|
| Age of Onset | 8 | 2006 | 71 | 0.260 |
Why?
|
| Sexual Behavior | 4 | 2020 | 46 | 0.250 |
Why?
|
| Retrospective Studies | 12 | 2018 | 2976 | 0.250 |
Why?
|
| Vietnam | 4 | 2007 | 7 | 0.250 |
Why?
|
| Survivors | 4 | 2020 | 69 | 0.250 |
Why?
|
| Risperidone | 1 | 2006 | 4 | 0.250 |
Why?
|
| Anger | 4 | 2009 | 32 | 0.250 |
Why?
|
| Referral and Consultation | 4 | 2019 | 82 | 0.240 |
Why?
|
| Personality Assessment | 9 | 2011 | 29 | 0.240 |
Why?
|
| Eszopiclone | 3 | 2011 | 3 | 0.230 |
Why?
|
| Association | 2 | 2004 | 4 | 0.230 |
Why?
|
| Spiritualism | 1 | 2005 | 1 | 0.230 |
Why?
|
| Yoga | 3 | 2020 | 10 | 0.220 |
Why?
|
| Imipramine | 9 | 1996 | 10 | 0.220 |
Why?
|
| Brain Mapping | 5 | 2014 | 123 | 0.220 |
Why?
|
| Cultural Characteristics | 5 | 2011 | 19 | 0.220 |
Why?
|
| Amygdala | 4 | 2014 | 34 | 0.220 |
Why?
|
| Sexual Dysfunctions, Psychological | 4 | 2002 | 10 | 0.220 |
Why?
|
| Recurrence | 8 | 2009 | 268 | 0.220 |
Why?
|
| Cognition Disorders | 3 | 2006 | 691 | 0.220 |
Why?
|
| Perception | 4 | 2015 | 63 | 0.210 |
Why?
|
| Learning | 3 | 2014 | 59 | 0.210 |
Why?
|
| Aripiprazole | 5 | 2012 | 7 | 0.210 |
Why?
|
| Sleep | 7 | 2019 | 267 | 0.210 |
Why?
|
| Chronic Disease | 6 | 2009 | 364 | 0.210 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2009 | 32 | 0.210 |
Why?
|
| Narration | 2 | 2018 | 12 | 0.210 |
Why?
|
| Hydrocortisone | 4 | 2015 | 28 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 168 | 0.200 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2003 | 12 | 0.200 |
Why?
|
| Grief | 3 | 2007 | 18 | 0.190 |
Why?
|
| Cost of Illness | 1 | 2003 | 43 | 0.190 |
Why?
|
| Violence | 2 | 2017 | 34 | 0.190 |
Why?
|
| Hyperthyroidism | 1 | 2002 | 10 | 0.190 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2000 | 7 | 0.190 |
Why?
|
| Amines | 2 | 2000 | 8 | 0.190 |
Why?
|
| Acetates | 2 | 2000 | 15 | 0.190 |
Why?
|
| Personality Development | 4 | 2001 | 5 | 0.180 |
Why?
|
| Alcoholism | 4 | 2018 | 64 | 0.180 |
Why?
|
| Psychiatry | 2 | 1999 | 12 | 0.180 |
Why?
|
| Orgasm | 5 | 2002 | 9 | 0.180 |
Why?
|
| Parents | 2 | 2018 | 106 | 0.180 |
Why?
|
| Reference Values | 7 | 2009 | 169 | 0.180 |
Why?
|
| Libido | 4 | 2002 | 6 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 4 | 2008 | 40 | 0.170 |
Why?
|
| Hypothyroidism | 1 | 2002 | 68 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2008 | 136 | 0.170 |
Why?
|
| Oxytocin | 2 | 2012 | 4 | 0.170 |
Why?
|
| Patient Dropouts | 5 | 2013 | 24 | 0.160 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2020 | 2 | 0.160 |
Why?
|
| Secondary Prevention | 3 | 2010 | 48 | 0.160 |
Why?
|
| Buspirone | 3 | 2009 | 4 | 0.160 |
Why?
|
| Mental Recall | 5 | 2019 | 48 | 0.160 |
Why?
|
| Telomere | 2 | 2013 | 6 | 0.160 |
Why?
|
| Single-Blind Method | 8 | 2008 | 86 | 0.160 |
Why?
|
| Rape | 1 | 2020 | 5 | 0.160 |
Why?
|
| Cocaine | 2 | 1991 | 31 | 0.160 |
Why?
|
| Prescription Drug Misuse | 1 | 2019 | 6 | 0.160 |
Why?
|
| Regression Analysis | 7 | 2013 | 216 | 0.160 |
Why?
|
| Clinical Trials as Topic | 12 | 2008 | 190 | 0.150 |
Why?
|
| Lung Diseases | 2 | 1999 | 36 | 0.150 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2019 | 3 | 0.150 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2011 | 26 | 0.150 |
Why?
|
| Age Factors | 8 | 2013 | 633 | 0.150 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 210 | 0.150 |
Why?
|
| Patient Health Questionnaire | 1 | 2019 | 11 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2019 | 64 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 18 | 0.150 |
Why?
|
| Heart Rate | 3 | 2015 | 103 | 0.150 |
Why?
|
| Antibodies, Bacterial | 3 | 1997 | 7 | 0.150 |
Why?
|
| Prefrontal Cortex | 3 | 2013 | 103 | 0.150 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 38 | 0.140 |
Why?
|
| Cross-Over Studies | 2 | 2011 | 64 | 0.140 |
Why?
|
| Inpatients | 1 | 2019 | 113 | 0.140 |
Why?
|
| Drug Synergism | 3 | 2017 | 38 | 0.140 |
Why?
|
| Propranolol | 2 | 2011 | 4 | 0.140 |
Why?
|
| Hierarchy, Social | 1 | 2018 | 4 | 0.140 |
Why?
|
| Appointments and Schedules | 1 | 1998 | 12 | 0.140 |
Why?
|
| Predictive Value of Tests | 4 | 2013 | 438 | 0.140 |
Why?
|
| Craving | 1 | 2018 | 3 | 0.140 |
Why?
|
| Heroin Dependence | 2 | 2004 | 9 | 0.140 |
Why?
|
| Occupational Diseases | 1 | 2018 | 21 | 0.140 |
Why?
|
| Schizophrenia | 7 | 2007 | 46 | 0.140 |
Why?
|
| Social Environment | 3 | 2013 | 66 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2019 | 73 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2018 | 3 | 0.140 |
Why?
|
| Resilience, Psychological | 2 | 2016 | 20 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2017 | 69 | 0.140 |
Why?
|
| Pseudomonas aeruginosa | 2 | 1997 | 40 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 3717 | 0.140 |
Why?
|
| Pain Management | 1 | 2019 | 126 | 0.130 |
Why?
|
| Child, Preschool | 9 | 2019 | 563 | 0.130 |
Why?
|
| Paired-Associate Learning | 1 | 1997 | 1 | 0.130 |
Why?
|
| Postmenopause | 3 | 2007 | 57 | 0.130 |
Why?
|
| N-Methylaspartate | 1 | 2017 | 2 | 0.130 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2017 | 2 | 0.130 |
Why?
|
| Low Back Pain | 1 | 2019 | 128 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 83 | 0.130 |
Why?
|
| Statistics as Topic | 5 | 2012 | 84 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 32 | 0.130 |
Why?
|
| Carbolines | 1 | 1997 | 1 | 0.130 |
Why?
|
| Cytokines | 2 | 2009 | 202 | 0.130 |
Why?
|
| Attitude to Health | 4 | 2009 | 90 | 0.130 |
Why?
|
| Occupational Health | 1 | 2017 | 16 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 3 | 2013 | 60 | 0.130 |
Why?
|
| Decision Making | 1 | 2018 | 174 | 0.120 |
Why?
|
| Child of Impaired Parents | 3 | 2006 | 9 | 0.120 |
Why?
|
| Social Identification | 1 | 2016 | 6 | 0.120 |
Why?
|
| Psychotic Disorders | 2 | 1996 | 29 | 0.120 |
Why?
|
| Temperament | 2 | 2013 | 11 | 0.120 |
Why?
|
| Self Concept | 2 | 2013 | 37 | 0.120 |
Why?
|
| Connectome | 1 | 2015 | 10 | 0.120 |
Why?
|
| Mental Health | 2 | 2017 | 94 | 0.120 |
Why?
|
| Social Behavior | 3 | 2013 | 50 | 0.120 |
Why?
|
| Yohimbine | 2 | 1993 | 6 | 0.120 |
Why?
|
| Saliva | 1 | 2015 | 47 | 0.110 |
Why?
|
| Visual Perception | 2 | 2013 | 21 | 0.110 |
Why?
|
| Reflex, Startle | 1 | 2014 | 4 | 0.110 |
Why?
|
| Florida | 1 | 2014 | 15 | 0.110 |
Why?
|
| Erectile Dysfunction | 2 | 2002 | 53 | 0.110 |
Why?
|
| Homicide | 2 | 2006 | 3 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 34 | 0.110 |
Why?
|
| Odorants | 2 | 2004 | 15 | 0.110 |
Why?
|
| Social Support | 3 | 2011 | 174 | 0.110 |
Why?
|
| Placebo Effect | 3 | 2019 | 10 | 0.110 |
Why?
|
| Constipation | 2 | 2012 | 16 | 0.110 |
Why?
|
| Neurotransmitter Agents | 2 | 2007 | 13 | 0.110 |
Why?
|
| Lithium | 3 | 1996 | 16 | 0.110 |
Why?
|
| Acid Sensing Ion Channels | 1 | 2014 | 2 | 0.110 |
Why?
|
| Antimanic Agents | 2 | 2004 | 7 | 0.110 |
Why?
|
| Conditioning, Classical | 1 | 2014 | 4 | 0.110 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 281 | 0.100 |
Why?
|
| RGS Proteins | 1 | 2013 | 2 | 0.100 |
Why?
|
| Animals | 8 | 2008 | 3255 | 0.100 |
Why?
|
| Weight Gain | 2 | 2012 | 60 | 0.100 |
Why?
|
| Love | 1 | 2013 | 1 | 0.100 |
Why?
|
| Awareness | 1 | 2013 | 37 | 0.100 |
Why?
|
| Lipid A | 3 | 1989 | 3 | 0.100 |
Why?
|
| Trust | 1 | 2012 | 8 | 0.100 |
Why?
|
| Respiratory Function Tests | 2 | 2006 | 25 | 0.090 |
Why?
|
| Antisocial Personality Disorder | 1 | 2012 | 8 | 0.090 |
Why?
|
| Phosphorus | 2 | 2004 | 7 | 0.090 |
Why?
|
| Memory | 4 | 2006 | 213 | 0.090 |
Why?
|
| Ejaculation | 2 | 1992 | 8 | 0.090 |
Why?
|
| Risk-Taking | 1 | 2012 | 28 | 0.090 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2012 | 9 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 60 | 0.090 |
Why?
|
| Narcotics | 2 | 2004 | 34 | 0.090 |
Why?
|
| L-Selectin | 2 | 2003 | 7 | 0.090 |
Why?
|
| Desipramine | 2 | 1989 | 3 | 0.090 |
Why?
|
| Administration, Oral | 6 | 2007 | 97 | 0.090 |
Why?
|
| Dehydroepiandrosterone | 3 | 2007 | 4 | 0.090 |
Why?
|
| Drive | 1 | 2011 | 1 | 0.090 |
Why?
|
| Imagination | 1 | 2011 | 3 | 0.090 |
Why?
|
| Home Care Services | 1 | 1991 | 21 | 0.090 |
Why?
|
| Pregabalin | 3 | 2005 | 14 | 0.080 |
Why?
|
| Algorithms | 4 | 2007 | 295 | 0.080 |
Why?
|
| Socioeconomic Factors | 6 | 2012 | 255 | 0.080 |
Why?
|
| Attitude to Death | 1 | 2010 | 8 | 0.080 |
Why?
|
| Valproic Acid | 2 | 2003 | 13 | 0.080 |
Why?
|
| Urinary Incontinence | 2 | 1992 | 21 | 0.080 |
Why?
|
| Cerebral Cortex | 3 | 2008 | 125 | 0.080 |
Why?
|
| Psychopathology | 2 | 2007 | 6 | 0.080 |
Why?
|
| Nuclear Family | 1 | 2009 | 8 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2008 | 126 | 0.080 |
Why?
|
| Drug Tolerance | 2 | 2005 | 6 | 0.080 |
Why?
|
| Sick Role | 3 | 2008 | 15 | 0.080 |
Why?
|
| S-Adenosylmethionine | 4 | 1990 | 5 | 0.080 |
Why?
|
| Riluzole | 1 | 2009 | 1 | 0.070 |
Why?
|
| Caribbean Region | 1 | 2009 | 2 | 0.070 |
Why?
|
| Spectrum Analysis | 1 | 2009 | 7 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 3 | 2006 | 42 | 0.070 |
Why?
|
| Neurobiology | 1 | 2009 | 5 | 0.070 |
Why?
|
| Logistic Models | 2 | 2015 | 350 | 0.070 |
Why?
|
| Lung Diseases, Obstructive | 3 | 1998 | 6 | 0.070 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 43 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2008 | 13 | 0.070 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2008 | 8 | 0.070 |
Why?
|
| Quetiapine Fumarate | 1 | 2008 | 3 | 0.070 |
Why?
|
| Electroconvulsive Therapy | 5 | 1996 | 16 | 0.070 |
Why?
|
| Dissociative Disorders | 1 | 2008 | 4 | 0.070 |
Why?
|
| 1-Naphthylamine | 2 | 1998 | 4 | 0.070 |
Why?
|
| Sensation | 1 | 1988 | 11 | 0.070 |
Why?
|
| Drug Design | 1 | 2008 | 21 | 0.070 |
Why?
|
| Demography | 1 | 2008 | 56 | 0.070 |
Why?
|
| Pattern Recognition, Visual | 1 | 2008 | 13 | 0.070 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2007 | 2 | 0.070 |
Why?
|
| Child Behavior Disorders | 2 | 2007 | 20 | 0.070 |
Why?
|
| Data Collection | 2 | 2005 | 80 | 0.070 |
Why?
|
| Affective Disorders, Psychotic | 1 | 2007 | 1 | 0.070 |
Why?
|
| Pregnancy, Unplanned | 1 | 2007 | 2 | 0.070 |
Why?
|
| Abortion, Spontaneous | 1 | 2007 | 10 | 0.070 |
Why?
|
| Managed Care Programs | 1 | 2007 | 5 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 1987 | 29 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2019 | 210 | 0.070 |
Why?
|
| Diarrhea | 1 | 2007 | 31 | 0.070 |
Why?
|
| Verapamil | 1 | 1987 | 25 | 0.070 |
Why?
|
| Anthropology, Cultural | 1 | 2007 | 4 | 0.070 |
Why?
|
| New York City | 1 | 2007 | 8 | 0.070 |
Why?
|
| Mice | 6 | 2001 | 1228 | 0.070 |
Why?
|
| Television | 1 | 2007 | 5 | 0.070 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2007 | 5 | 0.070 |
Why?
|
| Pituitary-Adrenal System | 1 | 2007 | 8 | 0.060 |
Why?
|
| Biliary Tract | 1 | 1986 | 3 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2007 | 20 | 0.060 |
Why?
|
| Cholecystitis | 1 | 1986 | 8 | 0.060 |
Why?
|
| Auditory Perception | 2 | 1999 | 31 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2005 | 123 | 0.060 |
Why?
|
| Chicago | 2 | 2019 | 811 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2008 | 218 | 0.060 |
Why?
|
| Antibody Specificity | 3 | 1994 | 20 | 0.060 |
Why?
|
| Albinism | 1 | 1986 | 1 | 0.060 |
Why?
|
| Schizophrenia, Disorganized | 1 | 1986 | 1 | 0.060 |
Why?
|
| Avoidance Learning | 2 | 2012 | 6 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 439 | 0.060 |
Why?
|
| Disasters | 1 | 2006 | 2 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 1994 | 75 | 0.060 |
Why?
|
| Chromosome Breakage | 1 | 2006 | 3 | 0.060 |
Why?
|
| Pregnancy | 1 | 2007 | 324 | 0.060 |
Why?
|
| Morphine | 1 | 1986 | 70 | 0.060 |
Why?
|
| Cohort Studies | 6 | 2008 | 1412 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2006 | 44 | 0.060 |
Why?
|
| Galvanic Skin Response | 2 | 2019 | 7 | 0.060 |
Why?
|
| Dysthymic Disorder | 1 | 2006 | 2 | 0.060 |
Why?
|
| Mass Media | 1 | 2006 | 10 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 26 | 0.060 |
Why?
|
| Sleep, REM | 1 | 2005 | 13 | 0.060 |
Why?
|
| Temporal Lobe | 1 | 2005 | 57 | 0.060 |
Why?
|
| Infant | 5 | 2019 | 478 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2006 | 69 | 0.060 |
Why?
|
| Neural Pathways | 2 | 2015 | 54 | 0.060 |
Why?
|
| Cyclothymic Disorder | 1 | 2004 | 1 | 0.060 |
Why?
|
| Basal Ganglia | 1 | 2004 | 13 | 0.050 |
Why?
|
| Demyelinating Diseases | 1 | 2004 | 12 | 0.050 |
Why?
|
| Cocaine-Related Disorders | 1 | 2004 | 13 | 0.050 |
Why?
|
| Hospitalization | 4 | 2005 | 285 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 290 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2007 | 258 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2004 | 42 | 0.050 |
Why?
|
| Social Behavior Disorders | 1 | 2004 | 5 | 0.050 |
Why?
|
| Parent-Child Relations | 2 | 2018 | 36 | 0.050 |
Why?
|
| Migraine Disorders | 1 | 2003 | 18 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2003 | 74 | 0.050 |
Why?
|
| Widowhood | 1 | 2003 | 1 | 0.050 |
Why?
|
| Developing Countries | 1 | 2003 | 13 | 0.050 |
Why?
|
| Epinephrine | 1 | 2003 | 29 | 0.050 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2002 | 4 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 94 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 164 | 0.050 |
Why?
|
| Indoles | 1 | 2002 | 32 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2003 | 217 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 55 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2005 | 546 | 0.050 |
Why?
|
| Antiparkinson Agents | 1 | 2002 | 41 | 0.050 |
Why?
|
| Emergency Service, Hospital | 2 | 2003 | 252 | 0.050 |
Why?
|
| Meprobamate | 1 | 1982 | 1 | 0.050 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 3 | 2007 | 5 | 0.050 |
Why?
|
| United Kingdom | 1 | 2002 | 40 | 0.050 |
Why?
|
| Headache | 1 | 1982 | 36 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 1982 | 66 | 0.050 |
Why?
|
| Interpersonal Relations | 2 | 2012 | 86 | 0.050 |
Why?
|
| Intestines | 1 | 2022 | 77 | 0.040 |
Why?
|
| Incidence | 4 | 2007 | 624 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2019 | 534 | 0.040 |
Why?
|
| Aspirin | 1 | 1982 | 48 | 0.040 |
Why?
|
| Hospitals, General | 2 | 2003 | 3 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2021 | 7 | 0.040 |
Why?
|
| Shyness | 1 | 2001 | 2 | 0.040 |
Why?
|
| Drug Interactions | 2 | 1993 | 35 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2001 | 19 | 0.040 |
Why?
|
| Drug Costs | 1 | 2000 | 8 | 0.040 |
Why?
|
| Attitude of Health Personnel | 2 | 1999 | 133 | 0.040 |
Why?
|
| Anxiety, Separation | 3 | 2006 | 3 | 0.040 |
Why?
|
| Diazepam | 2 | 1998 | 5 | 0.040 |
Why?
|
| Linear Models | 1 | 2000 | 193 | 0.040 |
Why?
|
| Speech | 2 | 2013 | 21 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2019 | 22 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 7 | 0.040 |
Why?
|
| Marital Status | 1 | 1999 | 9 | 0.040 |
Why?
|
| Dominance, Cerebral | 1 | 1999 | 14 | 0.040 |
Why?
|
| Fluvoxamine | 1 | 1999 | 2 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 235 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2000 | 94 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2019 | 25 | 0.040 |
Why?
|
| Employment | 1 | 1999 | 38 | 0.040 |
Why?
|
| Personal Satisfaction | 2 | 2012 | 39 | 0.040 |
Why?
|
| Aging | 1 | 2006 | 1100 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1999 | 97 | 0.040 |
Why?
|
| Hemolysis | 2 | 1989 | 5 | 0.040 |
Why?
|
| Cross Reactions | 2 | 1989 | 6 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2019 | 117 | 0.040 |
Why?
|
| Professional Practice | 1 | 1998 | 5 | 0.040 |
Why?
|
| Psychology, Clinical | 1 | 1998 | 5 | 0.040 |
Why?
|
| Hypochondriasis | 1 | 1998 | 1 | 0.040 |
Why?
|
| Social Work | 1 | 1998 | 11 | 0.040 |
Why?
|
| Educational Status | 1 | 1999 | 209 | 0.040 |
Why?
|
| Chemokines | 2 | 2009 | 15 | 0.040 |
Why?
|
| Feedback | 1 | 1998 | 33 | 0.040 |
Why?
|
| Professional-Patient Relations | 1 | 1998 | 28 | 0.040 |
Why?
|
| Internal Medicine | 1 | 1998 | 28 | 0.040 |
Why?
|
| Work | 1 | 2017 | 6 | 0.030 |
Why?
|
| Afghan Campaign 2001- | 1 | 2017 | 6 | 0.030 |
Why?
|
| Motivation | 1 | 1998 | 82 | 0.030 |
Why?
|
| Electroencephalography | 2 | 1995 | 70 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 298 | 0.030 |
Why?
|
| Benzamides | 1 | 1997 | 12 | 0.030 |
Why?
|
| Checklist | 1 | 2017 | 33 | 0.030 |
Why?
|
| Keratitis | 1 | 1997 | 2 | 0.030 |
Why?
|
| Eye Infections, Bacterial | 1 | 1997 | 9 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2019 | 126 | 0.030 |
Why?
|
| Blood Pressure | 3 | 2009 | 166 | 0.030 |
Why?
|
| Parenting | 1 | 2018 | 66 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 1997 | 32 | 0.030 |
Why?
|
| Absenteeism | 1 | 2017 | 1 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2017 | 5 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1997 | 67 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 70 | 0.030 |
Why?
|
| Bacteria | 2 | 1989 | 61 | 0.030 |
Why?
|
| Clozapine | 1 | 1996 | 5 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 1996 | 6 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 213 | 0.030 |
Why?
|
| Xerostomia | 2 | 2005 | 6 | 0.030 |
Why?
|
| Acute Disease | 2 | 1987 | 162 | 0.030 |
Why?
|
| Biomarkers | 2 | 2013 | 477 | 0.030 |
Why?
|
| Forecasting | 2 | 2007 | 78 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 1996 | 16 | 0.030 |
Why?
|
| Defense Mechanisms | 2 | 2006 | 4 | 0.030 |
Why?
|
| Pain Measurement | 1 | 1997 | 413 | 0.030 |
Why?
|
| Disease Susceptibility | 2 | 1998 | 56 | 0.030 |
Why?
|
| Epilepsies, Partial | 1 | 1995 | 11 | 0.030 |
Why?
|
| Rest | 1 | 2015 | 27 | 0.030 |
Why?
|
| Social Adjustment | 2 | 2012 | 20 | 0.030 |
Why?
|
| Observer Variation | 2 | 2006 | 82 | 0.030 |
Why?
|
| Suicide | 2 | 2005 | 12 | 0.030 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 2 | 2005 | 5 | 0.030 |
Why?
|
| Health Surveys | 2 | 2006 | 76 | 0.030 |
Why?
|
| Hypertension | 2 | 1987 | 163 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1994 | 1 | 0.030 |
Why?
|
| Bacterial Vaccines | 1 | 1994 | 3 | 0.030 |
Why?
|
| Carbohydrate Sequence | 1 | 1994 | 6 | 0.030 |
Why?
|
| Immunization | 1 | 1994 | 13 | 0.030 |
Why?
|
| Molecular Weight | 1 | 1994 | 22 | 0.030 |
Why?
|
| Boston | 2 | 2007 | 13 | 0.030 |
Why?
|
| Phagocytosis | 1 | 1994 | 25 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2007 | 107 | 0.030 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2013 | 2 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 183 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 5 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 3 | 0.030 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2013 | 11 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 56 | 0.030 |
Why?
|
| Sex Characteristics | 2 | 2007 | 85 | 0.030 |
Why?
|
| Problem Solving | 1 | 2013 | 38 | 0.030 |
Why?
|
| Leukocytes | 1 | 2013 | 30 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2013 | 56 | 0.020 |
Why?
|
| DNA | 1 | 2013 | 92 | 0.020 |
Why?
|
| Cholera | 1 | 1992 | 1 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 111 | 0.020 |
Why?
|
| Thyrotropin | 2 | 1990 | 47 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2013 | 100 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 1992 | 76 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 120 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1993 | 55 | 0.020 |
Why?
|
| Estradiol | 1 | 2012 | 52 | 0.020 |
Why?
|
| Counseling | 1 | 2012 | 39 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 48 | 0.020 |
Why?
|
| Infertility | 1 | 1992 | 7 | 0.020 |
Why?
|
| Penile Erection | 1 | 1992 | 25 | 0.020 |
Why?
|
| Lymphocyte Count | 2 | 2003 | 16 | 0.020 |
Why?
|
| Hippocampus | 1 | 2013 | 197 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 377 | 0.020 |
Why?
|
| Electromyography | 1 | 2011 | 67 | 0.020 |
Why?
|
| Urban Population | 2 | 2006 | 127 | 0.020 |
Why?
|
| Sibling Relations | 2 | 1971 | 2 | 0.020 |
Why?
|
| Random Allocation | 3 | 1989 | 103 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2003 | 231 | 0.020 |
Why?
|
| Receptors, Dopamine | 1 | 1990 | 8 | 0.020 |
Why?
|
| Prolactin | 1 | 1990 | 4 | 0.020 |
Why?
|
| Drug Overdose | 1 | 1990 | 2 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 1990 | 16 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 865 | 0.020 |
Why?
|
| Family Relations | 1 | 2009 | 12 | 0.020 |
Why?
|
| Self Report | 1 | 2010 | 194 | 0.020 |
Why?
|
| Language | 1 | 2009 | 57 | 0.020 |
Why?
|
| Species Specificity | 1 | 1989 | 34 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1989 | 51 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1989 | 93 | 0.020 |
Why?
|
| Macrophages | 1 | 1989 | 88 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 58 | 0.020 |
Why?
|
| Glucose | 1 | 2008 | 43 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 35 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1988 | 1 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2008 | 12 | 0.020 |
Why?
|
| Endotoxins | 1 | 1988 | 9 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 72 | 0.020 |
Why?
|
| Gyrus Cinguli | 1 | 2008 | 13 | 0.020 |
Why?
|
| Dexamethasone | 2 | 2003 | 34 | 0.020 |
Why?
|
| Epitopes | 1 | 1988 | 39 | 0.020 |
Why?
|
| Cerebellum | 1 | 2008 | 34 | 0.020 |
Why?
|
| Bereavement | 1 | 2007 | 5 | 0.020 |
Why?
|
| Nerve Net | 1 | 2008 | 34 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2008 | 52 | 0.020 |
Why?
|
| Mass Screening | 1 | 2009 | 159 | 0.020 |
Why?
|
| Cause of Death | 1 | 2007 | 54 | 0.020 |
Why?
|
| Pyridines | 1 | 2007 | 26 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 225 | 0.020 |
Why?
|
| Inflammation | 1 | 2009 | 226 | 0.020 |
Why?
|
| Respiratory Tract Infections | 2 | 1984 | 23 | 0.020 |
Why?
|
| Family Conflict | 1 | 2007 | 2 | 0.020 |
Why?
|
| Expressed Emotion | 1 | 2007 | 3 | 0.020 |
Why?
|
| Urination Disorders | 1 | 1987 | 7 | 0.020 |
Why?
|
| Imino Acids | 1 | 1986 | 1 | 0.020 |
Why?
|
| Technetium Tc 99m Disofenin | 1 | 1986 | 1 | 0.020 |
Why?
|
| Nepal | 1 | 2006 | 1 | 0.020 |
Why?
|
| Psychophysiology | 1 | 2006 | 5 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 1986 | 6 | 0.020 |
Why?
|
| Technetium | 1 | 1986 | 4 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 1986 | 13 | 0.020 |
Why?
|
| Vision Disorders | 1 | 1987 | 19 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1987 | 17 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1986 | 41 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2007 | 61 | 0.020 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1986 | 21 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 15 | 0.020 |
Why?
|
| Translating | 1 | 2006 | 2 | 0.020 |
Why?
|
| Body Weight | 1 | 1987 | 129 | 0.020 |
Why?
|
| Starvation | 1 | 2006 | 1 | 0.020 |
Why?
|
| Metaphor | 1 | 2006 | 2 | 0.020 |
Why?
|
| Nausea | 1 | 2006 | 24 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2006 | 15 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 20 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2006 | 92 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2006 | 31 | 0.020 |
Why?
|
| Women's Health | 1 | 2007 | 174 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 103 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2005 | 9 | 0.020 |
Why?
|
| Risk | 1 | 2006 | 160 | 0.020 |
Why?
|
| Axons | 1 | 2005 | 24 | 0.010 |
Why?
|
| Mandelic Acids | 1 | 1985 | 1 | 0.010 |
Why?
|
| Lithium Carbonate | 1 | 1985 | 2 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1985 | 12 | 0.010 |
Why?
|
| Tremor | 1 | 1987 | 93 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 1985 | 17 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2005 | 59 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1986 | 203 | 0.010 |
Why?
|
| General Surgery | 1 | 2005 | 50 | 0.010 |
Why?
|
| Phosphocreatine | 1 | 2004 | 1 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 8 | 0.010 |
Why?
|
| Phospholipids | 1 | 2004 | 9 | 0.010 |
Why?
|
| Substance Abuse Detection | 1 | 2004 | 4 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1984 | 9 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 20 | 0.010 |
Why?
|
| Fathers | 1 | 2005 | 21 | 0.010 |
Why?
|
| Calcium | 1 | 1987 | 325 | 0.010 |
Why?
|
| Hallucinations | 1 | 2005 | 38 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1985 | 57 | 0.010 |
Why?
|
| Marijuana Abuse | 1 | 2004 | 6 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 356 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2004 | 29 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2004 | 42 | 0.010 |
Why?
|
| Pedigree | 2 | 2001 | 50 | 0.010 |
Why?
|
| Chlorpromazine | 1 | 1964 | 4 | 0.010 |
Why?
|
| Spirituality | 1 | 2005 | 78 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 23 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 521 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2003 | 31 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2003 | 17 | 0.010 |
Why?
|
| Serotonin | 1 | 2003 | 22 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2003 | 22 | 0.010 |
Why?
|
| Rwanda | 1 | 2003 | 1 | 0.010 |
Why?
|
| Assertiveness | 2 | 1994 | 7 | 0.010 |
Why?
|
| Mothers | 1 | 2005 | 160 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2003 | 67 | 0.010 |
Why?
|
| Mental Processes | 1 | 1962 | 15 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2003 | 463 | 0.010 |
Why?
|
| Personal Health Services | 1 | 1981 | 1 | 0.010 |
Why?
|
| Sociology, Medical | 1 | 1981 | 2 | 0.010 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2001 | 3 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2001 | 2 | 0.010 |
Why?
|
| Lod Score | 1 | 2001 | 11 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2001 | 6 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 22 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2001 | 30 | 0.010 |
Why?
|
| Sociology | 1 | 1961 | 1 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2001 | 30 | 0.010 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 1980 | 1 | 0.010 |
Why?
|
| Steroid Hydroxylases | 1 | 1980 | 1 | 0.010 |
Why?
|
| Amantadine | 1 | 1980 | 1 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 2000 | 34 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 1990 | 11 | 0.010 |
Why?
|
| Genotype | 1 | 2001 | 246 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 255 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 28 | 0.010 |
Why?
|
| Influenza, Human | 1 | 1980 | 40 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2000 | 53 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2000 | 37 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 102 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 51 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2000 | 65 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1999 | 28 | 0.010 |
Why?
|
| Individuality | 1 | 1959 | 15 | 0.010 |
Why?
|
| Behavior | 1 | 1959 | 21 | 0.010 |
Why?
|
| Personality | 1 | 1959 | 42 | 0.010 |
Why?
|
| Psychophysiologic Disorders | 1 | 1998 | 6 | 0.010 |
Why?
|
| Pulmonary Ventilation | 1 | 1998 | 7 | 0.010 |
Why?
|
| Hospitals, Psychiatric | 2 | 1969 | 9 | 0.010 |
Why?
|
| Seizures | 2 | 1993 | 62 | 0.010 |
Why?
|
| Moclobemide | 1 | 1997 | 1 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1997 | 4 | 0.010 |
Why?
|
| Cornea | 1 | 1997 | 9 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1997 | 10 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1997 | 18 | 0.010 |
Why?
|
| Vaccination | 1 | 1997 | 26 | 0.010 |
Why?
|
| Monitoring, Ambulatory | 1 | 1995 | 16 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 1995 | 10 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1994 | 5 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 1994 | 10 | 0.010 |
Why?
|
| Patient Admission | 1 | 1994 | 18 | 0.010 |
Why?
|
| Carbamazepine | 1 | 1993 | 4 | 0.010 |
Why?
|
| Ice | 1 | 1992 | 1 | 0.010 |
Why?
|
| Food Microbiology | 1 | 1992 | 2 | 0.010 |
Why?
|
| Peru | 1 | 1992 | 3 | 0.010 |
Why?
|
| Vibrio cholerae | 1 | 1992 | 2 | 0.010 |
Why?
|
| Water Supply | 1 | 1992 | 3 | 0.010 |
Why?
|
| Drinking | 1 | 1992 | 6 | 0.010 |
Why?
|
| Water Microbiology | 1 | 1992 | 9 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1993 | 80 | 0.010 |
Why?
|
| Feces | 1 | 1992 | 80 | 0.010 |
Why?
|
| Personality Tests | 1 | 1991 | 5 | 0.010 |
Why?
|
| Radiography | 1 | 1993 | 523 | 0.010 |
Why?
|
| Attitude | 1 | 1991 | 31 | 0.010 |
Why?
|
| Birth Weight | 1 | 1971 | 38 | 0.010 |
Why?
|
| Barbiturates | 1 | 1990 | 1 | 0.010 |
Why?
|
| Ataxia | 1 | 1991 | 75 | 0.010 |
Why?
|
| Salicylates | 1 | 1990 | 6 | 0.000 |
Why?
|
| Alcoholic Intoxication | 1 | 1990 | 8 | 0.000 |
Why?
|
| Emergencies | 1 | 1990 | 27 | 0.000 |
Why?
|
| Acetaminophen | 1 | 1990 | 22 | 0.000 |
Why?
|
| Polymyxin B | 1 | 1989 | 1 | 0.000 |
Why?
|
| Salmonella | 1 | 1989 | 2 | 0.000 |
Why?
|
| Immune Sera | 1 | 1989 | 4 | 0.000 |
Why?
|
| Neurotic Disorders | 1 | 1969 | 14 | 0.000 |
Why?
|
| Affective Symptoms | 1 | 1969 | 11 | 0.000 |
Why?
|
| Escherichia coli | 1 | 1989 | 42 | 0.000 |
Why?
|
| Therapeutic Equivalency | 1 | 1989 | 1 | 0.000 |
Why?
|
| Pulse | 1 | 1987 | 3 | 0.000 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1986 | 7 | 0.000 |
Why?
|
| Diagnosis | 1 | 1966 | 16 | 0.000 |
Why?
|
| Catheterization | 1 | 1984 | 40 | 0.000 |
Why?
|
| Rorschach Test | 1 | 1964 | 1 | 0.000 |
Why?
|
| Intelligence | 1 | 1964 | 14 | 0.000 |
Why?
|
| Thinking | 1 | 1964 | 12 | 0.000 |
Why?
|
| Schizophrenic Psychology | 1 | 1964 | 13 | 0.000 |
Why?
|
| Pneumonia | 1 | 1984 | 61 | 0.000 |
Why?
|
| Convulsive Therapy | 1 | 1961 | 1 | 0.000 |
Why?
|
| 17-alpha-Hydroxypregnenolone | 1 | 1980 | 1 | 0.000 |
Why?
|
| Hydroxyprogesterones | 1 | 1980 | 1 | 0.000 |
Why?
|
| Steroid 21-Hydroxylase | 1 | 1980 | 1 | 0.000 |
Why?
|
| Androstenedione | 1 | 1980 | 4 | 0.000 |
Why?
|
| HLA Antigens | 1 | 1980 | 12 | 0.000 |
Why?
|
| Testosterone | 1 | 1980 | 27 | 0.000 |
Why?
|
| Influenza A virus | 1 | 1980 | 14 | 0.000 |
Why?
|
| Body Height | 1 | 1971 | 31 | 0.000 |
Why?
|
| California | 1 | 1960 | 35 | 0.000 |
Why?
|